Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER_GOV 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Esophageal Neoplasms 3Breast Neoplasms 3Recurrence 2Fallopian Tube Neoplasms 2Uterine Cervical Neoplasms 1Unresectable Non-small Cell Lung Cancer 1Thyroid Neoplasms 1Stomach Neoplasms 1Sexual Dysfunction, Physiological 1Radiation Injuries 1Prostatic Neoplasms 1Pilonidal Sinus 1Pain, Postoperative 1Pain 1Ovarian Neoplasms 1Neoplasm Metastasis 1Mouth Neoplasms 1Melanoma 1Lung Neoplasms 1Intestinal Diseases 1Head and Neck Neoplasms 1Endometrial Neoplasms 1Death 1Colonic Neoplasms 1Carcinoma, Ovarian Epithelial 1Carcinoma, Hepatocellular 1Adenocarcinoma 1

Interventions

endostar protein 1Surgical Procedures, Operative 1Endostatins 1Drug Therapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER_GOV × Unresectable Non-small Cell Lung Cancer × Surgical Procedures, Operative × Clear all
NCT06617936 2025-07-15

Tislelizumab Combined With Recombinant Human Endostatin Combined With Chemotherapy for Unresectable Stage III Non-small Cell Lung Cancer.

Shandong Public Health Clinical Center

Phase 2 Recruiting
36 enrolled
Thoracic

Unresectable Non-small Cell Lung Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡